Bifogade filer
Vicore Annual Report 2022
549300KTNBPTZLF01130-2022-12-31-en
549300KTNBPTZLF01130-2022-12-31-en.zip-viewer
Kurs
+13,33%
Likviditet
15,2 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-27 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2025-05-06 | - | Årsstämma |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-05 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2019-05-15 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2019-01-07 | - | Extra Bolagsstämma 2018 |
| 2018-10-19 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-13 | - | Årsstämma |
| 2018-05-09 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-10-19 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-11 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2017-05-10 | - | Årsstämma |
| 2017-05-10 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-27 | - | Extra Bolagsstämma 2017 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2016-10-13 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-08 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-27 | - | Årsstämma |
| 2016-04-15 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the potential of a new class of drugs - angiotensin II type 2-receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2022.
The Annual Report for the financial year 2022 is available on the company’s website: https://vicorepharma.com/investors/financial-reports/
For further information, please contact:
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore itself.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-05 08:00 CEST.